new
   What Are the Procurement Channels for Encorafenib (Braftovi)?
501
Jan 20, 2026

Encorafenib (Braftovi) is a targeted therapy indicated for the treatment of cancers with specific gene mutations, such as melanoma, colorectal cancer, and non-small cell lung cancer. As a prescription medication, its procurement and administration must be strictly conducted under medical supervision.

What Are the Procurement Channels for Encorafenib (Braftovi)?

Overseas Procurement

Patients may consult and purchase the drug at hospital pharmacies or licensed retail pharmacies in countries/regions where Encorafenib has been approved for marketing.

Given that drug prices may be affected by factors such as regional variations and exchange rate fluctuations, patients are advised to make a detailed budget and plan in advance before purchasing.

Procurement via Medical Service Institutions

Patients may consult domestic overseas medical service institutions that have established partnerships with international pharmacies or pharmaceutical manufacturers.

These institutions typically provide legitimate import channels, along with professional consulting and guidance services.

Precautions for Procuring Encorafenib (Braftovi)

Adhere to Medical Prescriptions Strictly and Purchase Only with a Valid Prescription

Encorafenib is exclusively indicated for patients with confirmed BRAF V600E or V600K mutations detected by FDA-approved testing methods.

A specialist physician must conduct an evaluation and issue a prescription prior to purchase. Self-procurement and self-administration are strictly prohibited.

Verify That Drug Information Matches the Prescription

Brand Name: BRAFTOVI®.

Generic Name: Encorafenib.

Dosage Form: 75 mg per capsule.

Manufacturer: Produced by Array BioPharma Inc., a subsidiary of Pfizer Inc.

Inspect Drug Packaging and Storage Conditions.

Check the outer packaging for integrity and signs of tampering.

Ensure that the desiccant packet inside the drug bottle is intact and has not been removed.

Encorafenib should be stored at room temperature (20°C–25°C). At the time of purchase, verify that the storage conditions of the pharmacy or hospital comply with this requirement.

How to Distinguish Authentic Encorafenib (Braftovi) from Counterfeit Products

Examine Outer Packaging and Labels

Print Quality: Authentic packaging features clear printing, uniform coloration, and standard font. Counterfeit packaging often has blurred printing, color discrepancies, and spelling errors.

Anti-Counterfeiting Labels: Check for official anti-counterfeiting labels or scannable barcodes/QR codes on the packaging for verification.

Approval Number: While the format of approval numbers varies by country, all legitimate medications must carry a number issued by the national drug regulatory authority, which can be verified through official channels.

Inspect the Medication Itself

Capsule Appearance: Authentic Encorafenib capsules are hard gelatin capsules with an off-white cap imprinted with a stylized "A" and a white body imprinted with "LGX 75mg". Carefully compare the capsule color and the clarity of the imprints.

Medication Characteristic: Capsules should be intact, without cracks, adhesion, or leakage of contents.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Encorafenib(BRAFTOVI)
For the treatment of melanoma, colorectal cancer (CRC), and non-small cell lung cancer (NSCLC).
RELATED ARTICLES
Adverse Reactions of Encorafenib (Braftovi)

Encorafenib (Braftovi) is a kinase inhibitor targeting BRAFV600E or V600K mutations, indicated for the treatment of...

Wednesday, January 21st, 2026, 09:21
What Are the Precautions for Encorafenib (Braftovi) Administration?

Encorafenib (Braftovi) is a kinase inhibitor targeting BRAF V600E or V600K mutations, indicated for use in...

Wednesday, January 21st, 2026, 09:19
Dosage and Administration of Encorafenib (Braftovi)

Encorafenib (Braftovi) is a kinase inhibitor indicated for use in combination with specific drugs to treat...

Wednesday, January 21st, 2026, 09:15
What Are the Indications for Encorafenib (Braftovi)?

Encorafenib (Braftovi) is an oral targeted therapy that belongs to the class of kinase inhibitors. It is primarily...

Wednesday, January 21st, 2026, 09:10
RELATED MEDICATIONS
Nivolumab and Relatlimab
Treatment of unresectable or metastatic melanoma in patients aged 12 years and...
TOP
1
Binimetinib
Kinase inhibitor used in combination with encorafenib for the treatment of BRAF...
TOP
2
Cobimetinib
Cotellic is indicated for the treatment of adult patients with melanoma...
TOP
3
Ipilimumab
Unresectable or metastatic melanoma in adult and pediatric patients aged 12...
Encorafenib
For the treatment of melanoma, colorectal cancer (CRC), and non-small cell lung...
Binimetinib
Adults with advanced or metastatic melanoma with BRAF V600E or V600K mutation.
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved